University of Wollongong
Browse

Inclusion of cost effectiveness in licensing requirements of new drugs: The fourth hurdle

Download (162.68 kB)
journal contribution
posted on 2024-11-14, 19:21 authored by R Taylor, M Drummond, Glenn SalkeldGlenn Salkeld, S Sullivan
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?

History

Citation

Taylor, R. S., Drummond, M. F., Salkeld, G. & Sullivan, S. D. (2004). Inclusion of cost effectiveness in licensing requirements of new drugs: The fourth hurdle. BMJ: British Medical Journal, 329 (7472), 972-975.

Journal title

BMJ (Clinical research ed.)

Volume

329

Issue

7472

Pagination

972-975

Publisher website/DOI

Language

English

RIS ID

111813

Usage metrics

    Categories

    Keywords

    human society

    Licence

    Copyright - All rights reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC